Description:
The use of chemical compounds in treatment of metastatic cancer and in reducing the unwanted toxicities of chemotherapeutic agents when used in combination
Application: Chemotherapy Adjuvant
Advantages/Benefits:
• This technology eliminates cyclophosphamide-associated toxicities
• This technology eradicates gMDSC-mediated cancer
• This technology eradicates gMDSC-mediated metastasis
Abstract: The global cancer drugs market is expected to reach $173 billion dollars by 2022. Chemotherapy is one of the most established segments of the cancer therapeutics market; and it is used in 22% of all cancer treatments. A two-month chemo regimen can cost more than $30,000 dollars, and while generally effective, it can cause a range of adverse side effects. Chemotherapy damages cancer cells by disrupting nucleic acid synthesis, DNA replication and cell division; but it also affects non-cancerous cells through these same mechanisms. Adjuvant treatments that eliminate primary cancer, concomitant metastasis, and chemo-induced side effects will be exceedingly valuable in the cancer drugs market.
Technology Summary: The use of chemical compounds in treatment of metastatic cancer and in reducing the unwanted toxicities of chemotherapeutic agents when used in combination, simultaneously eliminates granulocytic myeloid derived suppressor cell (gMDSC) mediated cancer, metastasis and cyclophosphamide associated toxicities. Currently, commercially available side effect management treatments only address the side effects of chemotherapy. antiemetic’s reduce the severity of nausea and vomiting; and blood cell growth factors are now available to fight infection, and reduce anemic fatigue.
Our technology’s ability to collectively address cancer pathology and the side effects of chemotherapy is a competitive advantage in the market. Novartis, Amgen and Roche are the largest players in the chemotherapeutics space with control of almost half of the market; but companies like AbbVie, Biogen Idec, GlaxoSmithKline, Sanofi, and Pfizer are looking to leverage promising compounds in their pipelines to increase market share in this growing space. Augusta University’s technology #2018-018 can be attractive to startups, companies looking to grow cancer therapy market share, or even market leaders with deep stage 2 and 3 pipelines. This technology allows Augusta University to benefit from a license agreement with a wide range of corporate partners.